Numerai GP LLC: OSK position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Numerai GP LLC on OSK, newest first. How the timeline and the estimate are built.
Numerai GP LLC held 0 OSK shares at 2026-06-30 per its 13F-HR filed 2026-08-14.
the latest 13F is the newest step
- period ended2026-06-3013F 0 sharesChange vs previous 13F -11,372 shares
13F-HR 0001214659-26-010378 filed by Numerai GP LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2026-03-3113F 11,372 sharesChange vs previous 13F -46,328 shares
0.17% of the 13F portfolio, value $1,674,072.
13F-HR 0001214659-26-006464 filed by Numerai GP LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F 57,700 sharesChange vs previous 13F +29,502 shares
0.87% of the 13F portfolio, value $7,248,851.
13F-HR 0001214659-26-001975 filed by Numerai GP LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-09-3013F 28,198 sharesChange vs previous 13F -6,199 shares
0.52% of the 13F portfolio, value $3,657,281.
13F-HR 0001214659-25-016630 filed by Numerai GP LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 34,397 sharesChange vs previous 13F -10,123 shares
0.56% of the 13F portfolio, value $3,905,435.
13F-HR 0001214659-25-012224 filed by Numerai GP LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 44,520 sharesChange vs previous 13F not available
0.79% of the 13F portfolio, value $4,188,442.
13F-HR 0001214659-25-007830 filed by Numerai GP LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).